Patients with rosacea experienced improvement with Emrosi, an oral minocycline hydrochloride extended-release product, ...

A low-dose (40 mg) modified formulation of minocycline hydrochloride (DFD-29) was better tolerated and more effective than doxycycline and placebo in patients with moderate to severe ...

Journey Medical (DERM) announced the launch of and the first prescriptions filled for Emrosi(TM) (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended ...

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for RosaceaEmrosi Initial Distribution Ongoing; First ...

Some monotherapies have significant differences in efficacy for vitiligo, whereas other modalities have similar efficacy between therapies.

FDA Approval of Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year ...

Q4 2024 Earnings Call Transcript March 26, 2025 Journey Medical Corporation beats earnings expectations. Reported EPS is ...

In contrast, enhanced management included an oral antibiotic (100 mg doxycycline or minocycline) administered twice daily for 12 weeks, followed by a topical antibiotic (1% clindamycin ...

The FDA approved Emrosi™ in November 2024, with a market launch anticipated in early spring of 2025. The treatment involves a 40 mg Minocycline Hydrochloride Modified-Release Capsule, combining ...